French Transparency Commission Recognises Efficacy of Zonegran® (zonisamide) Monotherapy

Eisai Europe Limited [Pressemappe]
Hatfield, England (ots/PRNewswire) – Transparency advice for Zonegran(R) (zonisamide) monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy, has been published by the … Lesen Sie hier weiter…

Ähnliche Beiträge:

  • Novel Once-Daily Epilepsy Treatment now Available in France
  • Eisai Enters Russian Market With Approval of First Product
  • New First-in-class Treatment Fycompa® Launches in Norway…
  • Eisai erhält Marktzulassung für Zonegran® (zonisamid) als
  • Eisai erhält von Europäischer Arzneimittelbehörde…